Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 2121-2129

  Abdallah, Ahmed ^a   Belal, Mohamed ^a   El Bastawisy, Ahmed ^b   Gaafar, Rabab ^b  

^a AL AZHAR UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Non small cell lung cancer; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; GEMCITABINE; VASCULOTROPIN 165;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84898904791     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2016     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Sun S, Schiller JH, Spinola M and Minnal JD: New molecularly targeted therapies for lung cancer. J Clin Invest 117: 2740-2750, 2007.
3. Galligioni E and Ferro A: Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 34 (Suppl 4): S3-S7, 2001.
4. Loureiro RM and D'Amore PA: Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev 16: 77-89, 2005.
5. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
6. Lei J, Jiang A and Pei D: Identification and characterisation of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1443: 400-406, 1998.
7. Park JE, Keller GA and Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-1326, 1993.
8. Dawson B and Trapp RG (eds): Basic and Clinical Biostatistics. 3rd edition. Lange Medical Books-McGraw Hill, New York, NY, 2001.
9. Auberger J, Loeffler-Ragg J, Wurzer W and Hilbe W: Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr Cancer Drug Targets 6: 271-294, 2006.
10. Ferrara N, Houck K, Jakeman L and Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18-32, 1992.
11. Ferrara N, Gerber HP and LeCounter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
12. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL and Schnitt SJ: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26: 86-91, 1995.
13. Matsuyama W, Hashiguchi T, Mizoguchi A, Iwami F, Kawabata M, Arimura K and Osame M: Serum levels of vascular endothelial growth factor depends on the stage of progression lung cancer. Chest 118: 948-951, 2000.
14. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60: 3088-3095, 2000.
15. Takigawa N, Segawa Y, Fujimoto N, Hotta K and Eguchi K: Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 18: 1251-1254, 1998.
16. Yuan A, Yu C, Luh K, Chen W, Lin F, Kuo S and Yang PC: Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative reverse transcription-PCR. Lab Invest 80: 1671-1680, 2000.
17. Kishiro I, Kato S, Fuse D, Yoshida T, Machida S and Kaneko N: Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology 7: 93-98, 2002.
18. Kaya A, Ciledag A, Gulbay BE, Poyraz BM, Celik G, Sen E, et al: The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 98: 632-636, 2004.
19. Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 183: 29-42, 2005.
20. Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, et al: Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50: 51-58, 2005.
21. Brattström D, Bergqvist M, Hesselius P, Larsson A, Lamberg K, Wernlund J, et al: Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 37: 57-63, 2002.
22. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and Yasumoto K: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115: 1007-1114, 1998.
23. Brattström D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, et al: Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 18: 1123-1127, 1998.
24. Niklińska W, Burzykowski T, Chyczewski L and Nikliński J: Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer 34 (Suppl 2): S59-S64, 2001.
25. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
26. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997.
27. Robinson CJ and Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853-865, 2001.
28. Dickinson PJ, Sturges BK, Higgins RJ, et al: Vascular Endothelial Growth Factor mRNA Expression and Peritumoral Edema in Canine Primary Central Nervous System Tumors. Vet Pathol 45: 131-139, 2008.
29. Berkman RA, Merrill MJ, Reinhold WC, et al: Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153-159, 1993.
30. Huang H, Held-Feindt J, Buhl R, Mehdorn HM and Mentlein R: Expression of VEGF and its receptors in different brain tumors. Neurol Res 27: 371-377, 2005.
31. Munaut C, Boniver J, Foidart JM and Deprez M: Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression. Neuropathol Appl Neurobiol 28: 452-460, 2002.
32. Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, Lupi G, Leocata P, Basolo F, Pingitore R, Parenti G and Fontanini G: Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 30: 118-125, 2004.
33. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K and Kotani Y: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34: 2041-2045, 1998.
34. Webb NJ, Bottomley MJ, Watson CJ, et al: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94: 395-404, 1998.
35. Banks RE, Forbes MA, Kinsey SE, et al: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77: 956-64, 1998.
36. Tokunaga T, Oshika Y, Abe Y, et al: Vascular endothelial growth factor (VEGF) mRNA isoform expression patterns is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77: 998-1002, 1998.
37. Oshika Y, Nakamura M, Tokunaga T, Ozeki Y, Fukushima Y, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Tamaoki N and Ueyama Y: Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 12: 541-544, 1998.
38. Zygalaki E, Tsaroucha EG, Kaklamanis L and Lianidou ES: VEGF Splice Variants and VEGFRs in NSCLC. Clinical Chemistry 53: 1433-1439, 2007.
39. Timotheadou E, Murray S, Linardou H, Vrettou A, Skrickova J, Kosmidis P, Skarlos D, Pectasides D and Fountzilas G: VEGF165, Bcl-2, p53, COX-2 and HER-family expression in patients with stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) and correlation with clinical outcome. J Clin Oncol 23 (Suppl 16): S7246, 2005.
40. Yuan A, Yu CJ, Kuo SH, et al: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis,patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19: 432-441, 2001.
41. Brattström D, Bergqvist M, Hesselius P, et al: Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 43: 55-62, 2004.
42. Bonnesen B, Pappot H, Holmstav J and Skov BG: Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis. Lung Cancer 66: 314-318, 2009.
43. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V and Topuz E: Serum vascular endothelial growth factor (VEGF) and Bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 24: 576-580, 2006.
44. Strauss GM and Cummings KM: Smoking-related adenocarcinoma of the lung: Now the most common cause of cancer death in the US. Am Soc Clin Oncol 22: 2567, 2003.
45. Farias E, Ranuncolo S, Cresta C, et al: Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 89: 389-394, 2000.
46. Gregorc V, Ludovini V, Pistola S, et al: Vascular endothelial growth factor serum levels (VEGFsl) in non-small cell lung cancer (NSCLC) patients: correlation with histology and stage. Ann Oncol 11: 124 (Abstr 566), 2000.
47. Laack E, Köhler A, Kugler C, et al: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13: 1550-1557, 2002.
48. Trapé J, Buxó J and de Olaguer JP: Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer. Clin Chem 49: 523-525, 2003.
49. Fontanini G, Boldrini L, Chinè S, Pisaturo F, Basolo F, Calcinai A, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G: Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79: 363-369, 1999.
50. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, Watanabe Y and Sasaki T: Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2: 1411-1416, 1996.
51. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, et al: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8: 72-79, 2001.
52. Stefanou D, Batistatou A, Arkoumani E, et al: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol 19: 37-42, 2004.
53. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, et al: Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53: 91-96, 2006.
54. Dziadziuszko R, Chyczewski L, Jassem E and Jassem J: Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC) - a preliminary report. Folia Histochem Cytobiol 39 (Suppl 2): 100-101, 2001.
55. Mattern J, Koomägi R and Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73: 931-934, 1996.
56. Shibusa T, Shijubo N and Abe S: Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4: 1483-1487, 1998.
57. Takanami I, Tanaka F, Hashizume T and Kodaira S: Tumor angiogenesis in pulmonary adenocarcinomas: relationship with basic fibroblast growth factor, its receptor, and survival. Neoplasma 44: 295-298, 1997.
58. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, et al: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in nonsmall cell lung carcinoma (NSCLCs): correlation with angiogenesis and survival. J Pathol 188: 369-377, 1999.
59. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne KJ, Scott PAE, Pezzella F, Georgoulias V, Harris AL and Gatter KC: Vascular endothelial growth factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4: 3017-3024, 1998.
60. Fontanini G, Vignati S, Boldrini L, Chinè S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865, 1997.
61. Sheng H, Aoe M, Doihara H, Andou A and Shimizu N: Prognostic value of vascular endothelial growth factor expression in primary lung carcinoma. Acta Med Okayama 54: 119-126, 2000.